Brainstorm Cell Therapeutics Statistics Share Statistics Brainstorm Cell Therapeutics has 9.84M
shares outstanding. The number of shares has increased by 48.61%
in one year.
Shares Outstanding 9.84M Shares Change (YoY) 48.61% Shares Change (QoQ) 39.19% Owned by Institutions (%) 16.31% Shares Floating 6.74M Failed to Deliver (FTD) Shares 31,272 FTD / Avg. Volume 2.27%
Short Selling Information The latest short interest is 566.39K, so 5.76% of the outstanding
shares have been sold short.
Short Interest 566.39K Short % of Shares Out 5.76% Short % of Float 6.24% Short Ratio (days to cover) 1.34
Valuation Ratios The PE ratio is 1.04 and the forward
PE ratio is -0.62.
Brainstorm Cell Therapeutics's PEG ratio is
-0.01.
PE Ratio 1.04 Forward PE -0.62 PS Ratio 14.2 Forward PS 0 PB Ratio -1.55 P/FCF Ratio -1.33 PEG Ratio -0.01
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Brainstorm Cell Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 0.04,
with a Debt / Equity ratio of -0.09.
Current Ratio 0.04 Quick Ratio 0.04 Debt / Equity -0.09 Debt / EBITDA n/a Debt / FCF -0.08 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $31.44K Profits Per Employee $430.48K Employee Count 27 Asset Turnover 0.46 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -86.62% in the
last 52 weeks. The beta is 0.11, so Brainstorm Cell Therapeutics's
price volatility has been higher than the market average.
Beta 0.11 52-Week Price Change -86.62% 50-Day Moving Average 1.02 200-Day Moving Average 1.43 Relative Strength Index (RSI) 28.66 Average Volume (20 Days) 1,380,150
Income Statement In the last 12 months, Brainstorm Cell Therapeutics had revenue of 849K
and earned 11.62M
in profits. Earnings per share was 2.19.
Revenue 849K Gross Profit 849K Operating Income n/a Net Income 11.62M EBITDA n/a EBIT n/a Earnings Per Share (EPS) 2.19
Full Income Statement Balance Sheet The company has 187K in cash and 720K in
debt, giving a net cash position of -533K.
Cash & Cash Equivalents 187K Total Debt 720K Net Cash -533K Retained Earnings -226.64M Total Assets 3.57M Working Capital -8.57M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -9.09M
and capital expenditures 0, giving a free cash flow of -9.09M.
Operating Cash Flow -9.09M Capital Expenditures n/a Free Cash Flow -9.09M FCF Per Share -1.71
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of 0% and 1369.02%.
Gross Margin 100% Operating Margin n/a Pretax Margin 1369.02% Profit Margin 1369.02% EBITDA Margin n/a EBIT Margin n/a FCF Margin -1071.02%
Dividends & Yields BCLI does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for BCLI is $30,
which is 4984.7% higher than the current price. The consensus rating is "Buy".
Price Target $30 Price Target Difference 4984.7% Analyst Consensus Buy Analyst Count 1
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Oct 1, 2024. It was a
backward
split with a ratio of 1:15.
Last Split Date Oct 1, 2024 Split Type backward Split Ratio 1:15
Scores Altman Z-Score -103.91 Piotroski F-Score 2
